1.Zannad F., Ferreira J.P., Pocock S.J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2021;385 (20):1883-1893.2.McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med.2019;381 (21):1995-2008.3.Filippatos G., Anker S.D., Böhm M. et al. Empagliflozin and serum CA125 in patients with heart failure: a biomarker analysis from the EMPEROR-Reduced trial. Eur J Heart Fail.2022;24 (3):514-524.4.Nunuez J., Miñana G., Bodí V. et al. Clinical utility of CA125 measurement in heart failure. Heart Fail Rev. 2020;25 (3):371-382.5.Heerspink H.J.L., StefánssonB.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383 (15):1436-1446.6.Malishev Yu.I., Tsymbalyuk A.F., Kalinin N.V. CA125 as a marker of systemic congestion in CHF: new horizons. Cardiology.2021;61 (5):67-73.7.Thomas M.C., Cooper M.E., Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol.2021;17 (4):220-232.8.McCullough P.A., ÖNeill W.W. Risk Prediction in Heart Failure and Kidney Disease: Biomarkers and Beyond. Rev Cardiovasc Med.2020;21 (4):531-543.9.Vereshchagin I.V., Semenov A.L., Krivchenko A.I. et al. Chronic heart failure and chronic kidney disease: clinical aspects of interaction. Therapeutic Archive.2020;92 (9):115-121.10.Bakris G.L., Agarwal R., Anker S.D. et al. Effect of finerenone on the outcome of chronic kidney disease in type 2 diabetes. N Engl J Med. 2020;383 (23):2219-2229.